les immunosuppresseurs

!"#$%&''()*+(,,-.++.(-+%
/!
1
0.+%&''()*+(,,-.++.(-+%
%
/1 ,234567879:6%;36328<5%
/1/ =3>96979:6%?%
" #$%&'()*+,-!./&!)0%/1*+,!1(!2$30+-*!&))/+*!4!(5&--*+,!-/2,0/,!-/2!16&))/+&,$!'*11/1(&2*!
" 75&--*+,!-/2!1(!38(-*!32$'0'*!%*!1(!2$30+-*!&))/+*!!9!-/2!1*!%$'1*+'8*)*+,!%*!1(!:;!4!!
(',&<(,&0+!=!3201&>$2(,&0+!%*-!?@!(1102$(',&>-!A@BCD!(/E&1&(&2*-F!
" #$%&'()*+,-!/,&1&-$-!%(+-!G!%0)(&+*-!,8$2(3*/,&./*-!4!!
! "!,2(+-31(+,(,&0+!%H025(+*-I!
! "!)(1(%&*-!J!'0)30-(+,*!&))/+0105&./*!4!,2(&,*)*+,!%*!G+%*!&+,*+,&0+!A,0E&'&,$!KFI!
!
/1@ -5A234567879:6%4BC3D879EF5%G5%<8%23A:645%9DDF65%?%
L+,&,$!2*'0++/*!'0))*!$,2(+5M2*!
!
!
7',&<(,&0+!%*!?@!8*13*2!
#/1,&31&'(,&0+!
N20%/',&0+!%*!'O,0P&+*-!%0+,!;1"G!
!
!
:QNRSTL!BL??U?7;:L!
!
?@!'O,0,0E&./*-!
!
!
/1# +BC3D8%G5%<H8B79I879:6%G54%0J%8<<:238B79>4%?%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%+9;68<%/%%%%%%%%%%%%%%%%%%%%%%%%%%%%+9;68<%@%
!!!!!!!!!!!!!!!!!!!!!!!!!:*'0++(&--(+'*!%*!1H75! ! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!B0-,&)/1(,&0+!
!!!!!!!!!!!!!!!7',&<(,&0+!%/!?@!4!<0&*!B(==!%$3*+%(+,*! ! !!!!!!!!!!!!!!!! !!BCGV!W!BC!VX"BCVY!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Z(',*/2!SZ"7@!!!!!!!!!!!!!!!!!!!!Z(',*/2-!73[!=!SZ"κ\!!
! !
! !
!
!
%
%
%
%
%
+9;68<%#%
T&5+(1!%*!32052*--&0+!%/!'O'1*!'*11/1(&2*!4!,2(+-&,&0+!][WTI!
%
+9;68<%K%
#&,0-*!*,!3201&>$2(,&0+!'10+(1*I!TO+,8M-*!%*!1H7CSI!
%
:$30+-*!8/)02(1*!
?\!A7'F!
N20%/',&0+!%*!'O,0P&+*!;1"G!
=!
B8(^+*!α!&+%/',&_1*!%/!:!J!1H;1-2

Pharmaetudes
2
.78A54%GL8B79I879:6%GF%0J%M=K%?%
" /52%49;68<%?%
o :*'0++(&--(+'*!75!*,!(',&<(,&0+!B(1'&+*/2&+*!52`'*!J!'0)31*E*!2$'*3,*/2!@B:WBCa!
o :*'0++(&--(+'*!>('&1&,$*!W!)01$'/1*-!%6(%8$-&0+!;B7#[b!?Z7[!
o B0)31*E*!B(!c!B(1)0%/1&+*!→!(',&<*!B(1'&+*/2&+*!./&!%$380-3802O1*!SZ7@'!
o SZ7@'!%$380-3802O1$!<(!d,2*!/+!>(',*/2!%*!@2(+-'2&3,&0+!%/!5M+*!%*!16;?G!
" @5%49;68<%?%
o 7',&<(,&0+!%*-!)01$'/1*-!%*!'0-,&)/1(,&0+!→!7--0'!(/![*2!-&5+(1!→!TO+,8M-*!;?G!30--&_1*!
o B*11/1*-!3(--*!%*!]X!J!][!
" #5%49;68<%?%
o ;?G!(',&<*!1*!?@!./&!16(!320%/&,*I!N2052*--&0+!%*!38(-*!][!J!TI!;)31&./*!1(!N20,$&+*!)"@R:!
o @R:!30/2!@(25*,!R>!:(3()O'&+*!
%
%
%
/1K +9754%GH8B79:6%G54%A296B9A8<54%B<84454%GH&+%?%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
?H1?"G!*-,!320%/&,*!1*!!1O)380'O,*!(',&<$!3(2!1H75!=!'0-,&)/1(,&0+I!
L11*!(5&,!-/2!-0+!:!!(',&<*!1(!'*11/1*!'&_1*!!-&5+(1!)&,05M+*!!)&,0-*I!
!T,033*!1(!-O+,8M-*!%H;1"G!3(2!_10'(5*!%/!5M+*!%*!,2(+-'2&3,&0+I!
!7'!(+,&"'8(^+*!α!!*)3d'8*!1(!2$(',&0+!;1"G!W!:I!
!;+8&_*!1(!<0&*!%H(',&<(,&0+!%/!?@!(/E&1&(&2*!3(2!1H;1"G!!*)3d'8*!1H*+,2$*!*+!)&,0-*I!
!L)3d'8*+,!1(!'*11/1*!%*!-O+,8$,&-*2!%*!1H7CS!!+*!-*!%&<&-*!3(-I!
!
/1N M<8449>9B879:6%AC82D8B:<:;9EF5%G54%&+%?%
&6C9O975F24%G5%<8%4P67CQ45%G5%<H&<"@%?%%
!?*-!(+,&'(1'&+*/2&+*-!4!&+8&_&,*/2-!%/!-&5+(1![I!
" M9B<:4A:2965%+R)=&''()b!).*-R0I!
" J8B2:<9DF4%,-*S-RTI!
&6C9O975F24%GF%49;68<%@%G5%B:479DF<879:6%?%%
!?*-!'02,&'0e%*-I!
Ag
transcription
R
LT
Inhibiteurs calcineurine
Ciclosporine, tacrolimus
Gène Il-2
Il-2
Il-2
Il-2
Il-2
Ac anti-Il-2 Rα
Sérolimus
Evérolimus
Signal mitogène
Inhibiteurs de
synthèse d'ADN

!"#$%&''()*+(,,-.++.(-+%
#!
3
" ,25G694:65%M*-JR)MU0I!
" ,25694:<:65%+*0(,-.=I!
" '37CP<A25G694:<:65%+*0('.=-*0I!
&6C9O975F24%G54%5>>574%A2:<9>32879>4%96GF974%A82%<H&<"@%?%%
!;+8&_*+,!1*!-&5+(1!a!%*!32052*--&0+!%/!'O'1*!'*11/1(&2*!
(I +92:<9DF4%-R,R'().%
.I32:<9DF4%M.-J&MR)%
_I 7'#0!%&2&5$-!'0+,2*!1(!'8(^+*!α!%/!:!;1"G!4!!
V849<9W9D8O%+&'(0.MJ%
=8B<9XFD8O%Y.)R,RZ%
&6C9O975F24%G5%<8%4P67CQ45%GHR=)%?%%
!;+8&_&,*/2-!%*!-O+,8M-*!%*-!_(-*-!3/2&./*-I!
" RX87C9:A2965%&'(-.0%
" 'PB:AC36:<875%D:>379<%M.00M.,J!===!
RF7254%&+%?%%
!7'!(+,&"1O)380'O,(&2*-!
!T$2/)-!301O'10+(/E!4!0_,*+/-!3(2!&))/+&-(,&0+!%/!4!!
! ! "!'8*<(1!4!0U',[*S0*V&).I!
! ! "!1(3&+!4!J[U'*S0*V(0&).I!
! ! 7!)(+&3/1*2!(<*'!32$'(/,&0+I!
!7'#0!)/2&+!(+,&"BCa4!
! ! 'F2:D:D8O"M=#%*-J[*M0*).%*\J#I!
!
@1 &DDF6:4FAA25445F24%96C9O975F24%G5%<8%4P67CQ45%GL&0"@%?!
?*-!)$%&'()*+,-!&+8&_(+,!1*!-$'2$,&0+!%6;?"G-0+,!1(!'&'10-302&+*!*,!1*!,('201&)/-b!,0/-!G!3$+$,2(+,!1*!
'O,031(-)*!%*-!?@!BCD!@8[!0f!&1-!&+8&_*+,!1(!,2(+-%/',&0+!%/!-&5+(1!'0+%/&-(+,!J!1(!-O+,8M-*!%6;?"GI!
!
@1/ +72FB7F25%BC9D9EF5]%A234567879:6]%G3<9I286B5%?%
%
@1/1/ M9B<:4A:2965%?%%
" BO'10-302&+*!7!
" T/_-,(+'*!+(,/2*11*!-O+,8$,&-$*!3(2!Tolypocladium,inflatum4!3*3,&%*!'O'1&./*!
" @2M-!1&3038&1*b!&+-01/_1*!%(+-!1H*(/!
" T3$'&(1&,$-!4!!
 +R)=&''()!<0&*!02(1*!=!3(2*+,$2(1*I!
o LE'&3&*+,!>02)*!02(1*!9!8/&1*!%*!)(e-!!_&0%&-30+&_&1&,$!!!(<*'!<(2&(,&0+-!
&+,*2&+%&<&%/*11*-!%*![X"GX!g!A'(2!,2M-!1&3038&1*!4!+$'*--&,*!%*-!-*1-!_&1&(&2*-F!!
o ?*!=!(+'&*+!)(&-!%*!−!*+!−!/,&1&-$I!
 ).*-R0!ANRF!+*!%&>>M2*!./*!3(2!1H*E'&3&*+,!4!8/&1*!%*!)(e-!=!8/&1*!%*!2&'&+!A9!@7b!-/2>(',(+,F!
*+!'0+,(',!(<*'!16*(/!!)&'20$)/1-&0+!A(/5)*+,(,&0+!_&0%&-30F!
^%'(3-/1*!)011*!%*!)&'20!$)/1-&0+!
!
@1/1@ J8B2:<9DF4%?%%
" ZhiXY!
" T/_-,(+'*!+(,/2*11*!-O+,8$,&-$*!3(2!/+!'8()3&5+0+!Streptomycesb!)('201&%*!
" ?(',0+*!)('20'O'1&./*!8O%20380_*!
" T3$'&(1&,$!4!,-*S-RT!<0&*!02(1*!*,!3(2*+,$2(1*!
%

Pharmaetudes
4
• M:6G979:64%G5%G3<9I286B5%?%%
" ?&-,*!;!
" N2*-'2&3,&0+!&+&,&(1*!80-3&,(1&M2*!%H/+*!<(1&%&,$!%*!Y!)0&-!
" N2*-'2&3,&0+!2*-,2*&+,*!(/E!-3$'&(1&-,*-!
" C$1&<2(+'*!4!J!1H0>>&'&+*!
" N(-!%20&,!%*!-/_-,&,/,&0+!*+,2*!T7SC;##US!*,!SLR:7?!
!
@1@ '3B8694D5%GH8B79:6%?%
@1@1/ R678;:694754%G5%<8%B8<B965F2965%?%%
!B&'10-302&+*!*,!,('201&)/-!!&+8&_&,&0+!%*!1(!-O+,8M-*!%*!1H;1"G!9!_10./*+,!1(!%$380-38(,(,&0+!%/!>(',*/2!%*!
,2(+-'2&3,&0+!30/2!1(!-O+,8M-*!%6;?"G!
SZ"7@!4!S/'1*02!Z(',02!7',&<(,02!?O)380@!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
?*!)$'(+&-)*!%6(',&0+!(/j0/2%68/&!2*,*+/!*-,!16&+8&_&,&0+!%*!1(!-O+,8M-*!%*!'*2,(&+*-!'O,0P&+*-b!*+!3(2,&'/1&*2!
'*11*!%6;?"G!3(2!1*-!1O)380'O,*-!@8[!4!
" '*-!;T!3$+M,2*+,!%(+-!1*!'O,031(-)*!*,!-*!1&*+,!J!/+*!&))/+038&1&+*!9!1(!'O'1038&1&+*!A*+kO)*F!30/2!1(!
'&'10-302&+*!*,!J!/+*!320,$&+*!(33*1$*!Zh\N!AZh!\&+%&+5!320,*&+F!30/2!1*!,('201&)/-I!
?*!'0)31*E*!320,$&+*!302,*/-*")$%&'()*+,!-*!1&*!J!1(!'(1'&+*/2&+*!*,!&+8&_*!-0+!(',&<&,$!380-38(,(-&./*b!'*!
./&!'0+%/&,!J!16(''/)/1(,&0+!%*!380-380320,$&+*-!3(2)&!1*-./*11*-!1*!SZ"7@!-0/-!>02)*!380-3802O1$*!./&!+*!3$+M,2*!
31/-!%(+-!1*!+0O(/!*,!+6&+%/&,!31/-!1(!-O+,8M-*!%6;?"GI!
?(!'&'10-302&+*!&+8&_*b!0/,2*!1(!-O+,8M-*!%6;?"Gb!'*11*!%6;?"a!*,!%6;?"Db!%/!]#"BTZ!*,!%/!@SZb!'O,0P&+*-!
&+,*2<*+(+,!+0,())*+,!%(+-!1*!2*j*,!%*!52*>>*-I!
U+!(/,2*!)$'(+&-)*!%6(',&0+!(!$,$!32030-$!4!*11*!(/5)*+,*2(&,!1(!-O+,8M-*!%*!@]Z"l!./&!(!%*-!32032&$,$-!
&))/+0-/332*--&<*-I!
%
@1# ,C82D8B:B96379EF5%?%
!
• V9:G94A:69O9<973%A82%I:95%:28<5%?%
o #$%&0'2*!4!!
! "!'&'10-302&+*!T7SC;##US!9!aXgb!!
Ag
transcription
R
LT
Gène Il-2
CPA
costimulation
NOYAU
Synthèse d'Il-2
 Ca++
calmoduline
ciclosporine
tacrolimus
Cyclo
philline
FKBP
binding
protein
NF-AT
P
NF-AT
NF-AT

!"#$%&''()*+(,,-.++.(-+%
N!
5
!!!!!!!!!!!SLR:7?!9!DXg!A)&'2050/,,*1*,,*-W8/&1*!%*!2&'&+F!
! "!,('201&)/-!9!GX!J!Gig!
! "!-&201&)/-!9![ig!
o T/j*,,*!J!%*-!<(2&(,&0+-!&+,*2&+%&<&%/*11*-!!3(-!%*!30-0105&*!m-,(+%(2%m!CRSB!)0+&,02(5*!*,!
-/2<*&11(+'*!3*2)(+*+,-!
!
• J2864A:27%G864%<5%486;%?%
o B*-!-/_-,(+'*-!-*!'0+'*+,2*+,!%(+-!1*-!$1$)*+,-!>&5/2$-!%/!-(+5!A$2O,820'O,*-b!1*/'0'O,*-F!*+<I!iXg!
o C0-(5*!-/2!1*!-(+5!,0,(1!'(2!*+<&20+!1(!)0&,&$!%*!1(!%0-*!*-,!2*,20/<$*!%(+-!1*-!$1$)*+,-!>&5/2$-!
!
• '378O:<94879:6%?%
o n$3(,&./*!
o #01$'/1*-!)$,(_01&-$*-!3(2!1*!BoNa7D!*+!)$,(_01&,*-!0EO5$+$-!%0+,!'*2,(&+-!30--M%*+,!/+*!(',&<&,$!4!!
! "!+0)_2*/-*-!&+,*2(',&0+-!)$%&'()*+,*/-*-!
! "!(%(3,(,&0+!%*-!%0-*-!102-./*!B9B<:4A:2965!57!492:<9DF4!:F%3I32:<9DF4!-0+,!(--0'&$-!
%
• .<9D96879:6%?%#(j02&,(&2*)*+,!_&1&(&2*%
• J3287:;363B973%?%1(!'&'10-302&+*!+6(/2(&,!3(-!%6*>>*,!,$2(,05M+*b!)(&-!1*!,('201&)/-!16*-,!'8*k!'*2,(&+*-!
*-3M'*-!(+&)(1*-!%0+'!B;!3%,!1(!520--*--*%
!
@1K .>>574%96G34928O<54%?%
!
@1K1/ '82;5%7C328A5F79EF5%372:975%
" @0E&'&,$!!=*+.%R=_`(RJ.!!;+*>>&'('&,$!%*!1H;T!A2*j*,F!
" CH(/,(+,!31/-!320_1$)(,&./*!./H&1!O!(!%*-!<(2&(,&0+-!&+,*2&+%&<&%/*11*-!
" S$'*--&,$!%*!>(&2*!%*-!%0-(5*-!-(+5/&+-!>2$./*+,-!A-/2<*&11(+'*F!
!
@1K1@ .&%B:DDF64%a%7:F4%<54%&+%?%
• %=(%-&+`(.%&)T.MJ&.(Z!4!! !
! "!&+>*',&0+-!(3302,$*-!3(2!1*!52*>>0+!A,*-,-!-/2!1*!CF!
! "!2$(',&<(,&0+!'8*k!1*!:!%*!<&2/-!1(,*+,-!AB#pb!IIIF!
! "!&+>*',&0+-!03302,/+&-,*-!
• %=(%-&+`(.%MR-M&)*Sb).!4!! !
! "!1O)380)*-b!'(+'*2-!'/,(+$-I!
! "!1*!T;!%$,2/&,!,0/,*-!1*-!'*11/1*-!%$>02)$*-!4!(_-*+'*!!!2&-./*!%*!'(+'*2I!
! "!;T!/,&1&-$-!*+!,2(&,*)*+,!'820+&./*!%0+'!!2&-./*I!
!
@1K1# .&%4A3B9>9EF54%?%
!
)3AC2:7:W9B973%AC"%3%,F!
[JR%
M9B<:4A:2965%
===!AiXgF!
===!AGX"aXgF!
J8B2:<9DF4!
=!
=!
!
!
!